Home > Products > Featured products
Cat. No. Product name CAS No.
DC45278 Colivelin Featured

Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

867021-83-8
DC45287 TRPC6-PAM-C20 Featured

TRPC6-PAM-C20 is a selective TRPC6 positive allosteric modulator. TRPC6-PAM-C20 selectively activates TRPC6 over other TRP channels and also activates TRPA1. TRPC6-PAM-C20 induces transient increase in intracellular Ca2+ in HEK cells expressing TRPC6 (EC50=2.37 μM).

667427-75-0
DC45295 Inecalcitol Featured

Inecalcitol (TX 522), a unique vitamin D3 analog, is an orally active vitamin D receptor (VDR) agonist. Inecalcitol can induce cell apoptosis and has potent anticancer activities[3.

163217-09-2
DC55003 XY028-140 (MS140) Featured

XY028-140 (MS-140) is a potent and selective PROTAC-based CDK4/CDK6 kinase degrader. XY028-140 specifically inhibits RB-E2F signaling and reduces CDK4 and CDK6 protein levels in a dose- and time-dependent manner in vitro. In addition, XY028-140 can degrade its targets by linking them with ubiquitin-proteasome mechanism. Further, the degradation of CDK4/6 protein by XY028-140 is specifically mediated by CRBN. Therefore, XY028-140 effectively and selectively inhibits and degrades CDK4/6 kinase by targeting CDK4/6 kinase in CDK4/6i-S (CDK4/6 inhibitor-sensitive) tumor cells to the CRL4-CRBN-E3 ubiquitin complex. Compared with CDK6 wild-type cells, XY028-140 treatment of cells expressing wild-type or mutation-activated CDK6 resulted in a more effective degradation of CDK6 (S178P).

2229974-83-6
DC45317 EGFR/ErbB-2/ErbB-4 inhibitor-2 Featured

EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM.

179248-61-4
DC45318 Aurora kinase inhibitor-2 Featured

Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively.

331770-21-9
DC45324 Sofpironium bromide Featured

Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes.

1628106-94-4
DC45326 CCG-100602 Featured

CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF.

1207113-88-9
DC55030 NL1 Featured

NL1 is a select bacterial cystathionine γ-lyase (bCSE) inhibitor with IC50 of 5.8 μM (29.2 μM against hCSE). NL1 potentiates bactericidal antibiotics against pathogens.

DC55032 NL2 Featured

NL2 is a select bacterial cystathionine γ-lyase (bCSE) inhibitor with IC50 of 1.8 μM (25.3 μM against hCSE). NL2 potentiates bactericidal antibiotics against pathogens.

DC55035 NL3 Featured

NL3 is a select bacterial cystathionine γ-lyase (bCSE) inhibitor with IC50 of 0.7 μM (3.4 μM against hCSE). NL3 potentiates bactericidal antibiotics against pathogens.

DC55036 AS-99 Featured

AS-99 is a first-in-class and selective ASH1L (absent, small, or homeotic-like 1) inhibitor with IC50 of 0.79  µM. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden.

DC55038 BT-2 Featured

BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC)[1]. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM[2].

34576-94-8
DC55050 SJ6986 Featured

SJ6986 is a potent, selective, and orally bioavailable GSPT1/2 degrader with DC50 of 2.1 nM. SJ6986 demonstrates antiproliferative activity in MV4-11 and MHH-CALL-4 cell lines with IC50 of 1.5 nM and 0.4 nM, respectively.

2765625-93-0
DC45372 Dodecylphosphocholine Featured

Dodecylphosphocholine is a detergent widely utilized in NMR studies of membrane proteins.

29557-51-5
DC60410 CID91585 Featured

2-(2,6-Dioxopiperidin-3-yl)phthalimidine (EM-12), a teratogenic Thalidomide analogue, is more active than Thalidomide and is much more stable for hydrolysis. 2-(2,6-Dioxopiperidin-3-yl)phthalimidine enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas.

26581-81-7
DC45418 Lipase Substrate Featured

Lipase Substrate is a substrate of lipase to detect activity.

195833-46-6
DC45456 FBPase-1 inhibitor-1 Featured

FBPase-1 inhibitor-1 (compound 1) is a novel allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1).

883973-99-7
DC45527 Avexitide Featured

Avexitide (Exendin (9-39)) is a specific and competitive antagonist of glucagon-like peptide-1 (GLP-1) receptor.

133514-43-9
DC45530 BSJ-4-116 Featured

BSJ-4-116 is a specific degrader of cyclin-dependent kinase 12 (CDK12). BSJ-4-116 exhibits potent antiproliferative effects.

2519823-34-6
DC45531 ICCB-19 hydrochloride Featured

ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy.

1803605-68-6
DC55020 MK-8153 Featured

MK-8153 is a potent and selective ROMK (potassium channel, Kir1.1) blocker with IC50 of 2.5 nM in rat ROMK, rKir1.1/HEK293 cells. MK-8153 has a longer projected human half-life (~14 h) than MK-7145, which should provide a reduced peak-to-trough exposure ratio and potentially, a smoother, more extended diuretic response.

1548286-45-8
Page 282 / Total 444 FirstPrevNextLastGoto